<DOC>
	<DOCNO>NCT03033394</DOCNO>
	<brief_summary>Currently UK , TDM routinely perform aminoglycosides glycopeptide antimicrobial agent , give fear narrow therapeutic window agent serious adverse event associate toxicity . However , critical care role TDM optimisation therapy demonstrate help optimise dose patient tend variable pharmacokinetic parameter ( J . A. Roberts et al , ) . This grow importance give low concentration antimicrobial agent , micro-organisms minimum inhibitory concentration ( MIC ) believe major driver AMR . The investigator set explore whether similar observation PK-PD target variability currently observe across secondary care set ( outside critical care ) whether appear impact clinical outcome .</brief_summary>
	<brief_title>Beta-lactam Pharmacokinetics Secondary Care</brief_title>
	<detailed_description>3.1 STUDY PARTICIPANTS - Drug level sample undertaken within first 120 hour commence antimicrobial therapy steady state ( least 4-5 dos administer treatment ) . - All patient consent use participation information leaflet consent form provide appendix 1 . 3.2 DRUG LEVEL SAMPLING - An extra 3mls blood collect patient 's routine daily phlebotomy round follow consent . They enrol 72 hour two day routine blood test ( whichever short ) . Up 10 sample may take 2 day patient enrol , depend number routine blood test patient receives day . No 3mls take per routine blood sample . For example , individual routine blood test take 8am day 1 day 2 . Then two extra sample take ( 3mls D1 3mls D2 ) . - The time receive dose antimicrobial , length infusion time , time sample collect record . - PK/PD index evaluation time minimum inhibitory concentration ( T &gt; MIC ) 3.3 SAMPLE PREPARTION AND ANLYSIS - All blood sample allow clot 15 minute room temperature centrifuge 2,400rpm 10 minute . Sera sample separate three vial store -800C . - Beta-lactam concentration measure use validate high-performance liquid chromatography method . 3.4 PHARMCOKINETIC-PHARMACODYNAMIC MODELLING - Data anonymized analyzed use Pmetrics R. - Different pharmacokinetic model explore use built statistical analysis option visual predictive check . - Pharmacodynamic model incorporate model use evidence identify literature selection parameter . - Monte Carlo simulation use simulation target attainment analysis pharmacodynamic outcome</detailed_description>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Adult subject 18 year old Capacity consent participation Receiving target antimicrobial less 120 hour OR receive target antimicrobial surgical prophylaxis . Appropriate venous access ( venous access gain ) Children 18 year old Lacking capacity prisoner Anaemia bleeding disorder , deem significant patient physician Patients physician deem suitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>